Cowen Starts Corvus Pharmaceuticals (CRVS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
- Exclusive-China's DeepSeek developing its own AI chip, sources say
BTIG Starts Corvus Pharmaceuticals (CRVS) at Buy
April 19, 2016 6:47 AM EDTBTIG initiated coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Buy rating and a price target of $22.00. Analyst Hartaj Singh is bullish on management and lead compound CPI-444.
"The company has two most important characteristics that we look for in early-stage biotech companies, (1)... More
Guggenheim Starts Corvus Pharmaceuticals (CRVS) at Buy
April 18, 2016 7:26 AM EDTGuggenheim initiated coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Buy rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Corvus Pharmaceuticals click here. For more ratings news on Corvus Pharmaceuticals click here.
Shares of Corvus Pharmaceuticals closed at $15.61 yesterday.
... MoreCredit Suisse Starts Corvus Pharmaceuticals (CRVS) at Outperform
April 18, 2016 6:39 AM EDTCredit Suisse initiates coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Outperform rating and a price target of $25.00.
Analyst V. Divan commented, "We see CRVS as a compelling earlystage immuno-oncology (I-O) opportunity that is relatively higher risk but that also offers a potentially high reward. CRVS's lead compound,... More
